medical journals

By Ryan McGuire, Senior Research Analyst Pharmaceutical companies are growing more strategic in their investigator initiated trial (IIT) selection. As Research and Development organizations have sharpened their focus on mission-critical pre-approval...

This is the first blog entry in a two-part series on journal selection. By Ryan McGuire,Senior Research Analyst Evaluating the medical journal landscape is the first step toward making sure manuscripts find their way to the appropriate home. In fact,...

While sponsors maintain editorial distance from investigators' findings, they increasingly push researchers to take action on publication Published data from investigator-initiated trials (IIT) have proven extremely valuable for both scientific and commercial...

By Ryan McGuire,Senior Research Analyst A study published in the British Medical Journal has received a lot of attention lately. It highlighted the prevalence of financial conflicts of interest (COI) for researchers sitting on 14 specific guideline-setting...

The Biologics Price Competition and Innovation Act (BPCI), passed by Congress in 2009, was intended by its sponsors to reign in the rising healthcare cost. Two years later the FDA still has not established complete guidance on an abbreviated pathway for biosimilars...